RxDoctor Payments DataLook up a doctor →

Joseph Mathews, MD

Endocrinology, Diabetes & Metabolism · Summerville, SCNPI 1811123300

Payments from drug & device makers

$296,698in general payments, 2019–2025

Across 1,156 payments — averaging $256.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Corcept Therapeutics$92K
  • AbbVie$92K
  • Novo Nordisk$22K
  • AstraZeneca$22K
  • Lilly USA, LLC$19K
  • Boehringer Ingelheim$10K
  • plus $41K from 53 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Corcept Therapeutics129$91,890
AbbVie61$91,718
Novo Nordisk103$22,096
AstraZeneca(2 entities)95$21,619
Lilly USA, LLC149$18,849
Boehringer Ingelheim40$9,592
Johnson & Johnson25$7,821
Sanofi-aventis U.S. LLC53$7,644
Xeris Pharmaceuticals, Inc.61$5,970
Amgen(2 entities)79$5,633
Shire North American Group Inc7$4,676
Recordati_rare_diseases_inc.7$1,854
Insulet Corporation50$1,512
Abbott54$1,068
Medtronic(2 entities)22$447
Mannkind Corporation22$410
Astellas Pharma US Inc17$329
BETA Bionics, Inc.11$329
Radius Health, Inc.14$259
IBSA Pharma Inc.16$253
Dexcom, Inc.9$249
Cequr Corporation5$222
Antares Pharma, Inc.10$155
Tandem Diabetes Care, Inc.8$154
Endo Pharmaceuticals Inc.10$147
Merck10$143
Valeritas, Inc.8$132
Novartis7$129
Ultragenyx Pharmaceutical Inc.6$119
Nestle Healthcare Nutrition Inc.5$106
Ascensia Diabetes Care US Inc.4$98
Amarin Pharma, Inc.5$96
Amneal Pharmaceuticals LLC5$82
Bayer5$79
OPKO Pharmaceuticals, LLC4$72
Renalytix AI, Inc.3$70
Esperion Therapeutics, Inc.4$56
Neurocrine Biosciences, Inc.2$48
Zealand Pharma US, Inc.2$46
Boston Scientific2$46
EUSA Pharma (US) LLC2$44
Regeneron Healthcare Solutions, Inc.3$41
Takeda Pharmaceuticals U.S.A., Inc.2$40
Esteve Pharmaceuticals LLC2$35
BD2$34
Clarus Therapeutics Inc.2$30
Aytu Biopharma, Inc.1$28
Vistapharm, Inc.2$27
Ascendis Pharma Endocrinology Inc1$23
Curonix LLC1$22
Arkray USA, Inc.1$21
Lifescan, Inc.1$20
Globus Medical1$20
Sun Pharmaceutical Industries Inc.1$18
Amryt Pharma Holdings Ltd1$18
Madrigal Pharmaceuticals1$18
Acella Pharmaceuticals, LLC1$15
Currax Pharmaceuticals LLC1$13
Acerus Pharmaceuticals Corporation1$13

How this compares

$296,698 in reported general payments places this provider in the 85th percentile of 99 endocrinology, diabetes & metabolism providers in South Carolina.

See all endocrinology, diabetes & metabolism providers in South Carolina →

Medicare billing

Part B allowed, 2024
$617,684
Medicare patients
1,002
Services billed
12,260

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Summerville

See the full list for South Carolina →

Where these figures come from

Is this you, or does something look wrong? →